Pharma Launch Secrets
First-in-Class vs Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
First-in-Class vs Me-Too Launch Differences and the Role of Content, Hyperpersonalization, and Technology with Frank Dolan, Founder and CEO of ARSENAL
•EP 11
00:00/00:00
October 26, 2022
First-in-Class vs Me-Too Launch Differen...
First-in-class medications are often referred to as innovative treatment alternatives. But innovation might scare and push away some HCPs and patients. In this episode of Pharma Launch Secrets, Bozidar is joined by Frank Dolan, Founder, and CEO of ARSENAL